Selected research
Industry Growth & Trends
Global Obstetrics and Gynecology Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Obstetrics and Gynecology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Obstetrics and Gynecology Drugs market include Abbott, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Bayer and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Obstetrics and Gynecology Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Obstetrics and Gynecology Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Obstetrics and Gynecology Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Obstetrics and Gynecology Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Obstetrics and Gynecology Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Obstetrics and Gynecology Drugs Market by Company
Abbott
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Bayer
Amgen
Abbvie
AstraZeneca
TherapeuticsMD
Lupin
GlaxoSmithKline
Ferring
Obstetrics and Gynecology Drugs Segment by Type
Hormonal Therapy
Non-Hormonal Therapy
Obstetrics and Gynecology Drugs Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Obstetrics and Gynecology Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Obstetrics and Gynecology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Obstetrics and Gynecology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Obstetrics and Gynecology Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Obstetrics and Gynecology Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Hormonal Therapy
- Non-Hormonal Therapy
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Abbott
- Johnson & Johnson
- Novartis
- Merck
- Roche
- Eli Lilly
- Pfizer
- Bayer
- Amgen
- Abbvie
- AstraZeneca
- TherapeuticsMD
- Lupin
- GlaxoSmithKline
- Ferring
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Obstetrics and Gynecology Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Obstetrics and Gynecology Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Obstetrics and Gynecology Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Obstetrics and Gynecology Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Obstetrics and Gynecology Drugs Market Size (2021-2032)
- 1.5.1 North America Obstetrics and Gynecology Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Obstetrics and Gynecology Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Obstetrics and Gynecology Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Obstetrics and Gynecology Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Obstetrics and Gynecology Drugs Market Size Growth Rate (2021-2032)
2 Obstetrics and Gynecology Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Hormonal Therapy
- 2.1.2 Non-Hormonal Therapy
- 2.2 Global Obstetrics and Gynecology Drugs Market Size by Type
- 2.2.1 Global Obstetrics and Gynecology Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Obstetrics and Gynecology Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Obstetrics and Gynecology Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Obstetrics and Gynecology Drugs Market Size by Regions
- 2.3.1 North America Obstetrics and Gynecology Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Obstetrics and Gynecology Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Obstetrics and Gynecology Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Obstetrics and Gynecology Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Obstetrics and Gynecology Drugs Market Size Breakdown by Type (2021-2026)
3 Obstetrics and Gynecology Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital Pharmacies
- 3.1.2 Online Pharmacies
- 3.1.3 Retail Pharmacies
- 3.2 Global Obstetrics and Gynecology Drugs Market Size by Application
- 3.2.1 Global Obstetrics and Gynecology Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Obstetrics and Gynecology Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Obstetrics and Gynecology Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Obstetrics and Gynecology Drugs Market Size by Regions
- 3.3.1 North America Obstetrics and Gynecology Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Obstetrics and Gynecology Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Obstetrics and Gynecology Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Obstetrics and Gynecology Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Obstetrics and Gynecology Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Obstetrics and Gynecology Drugs Industry Trends
- 4.2 Obstetrics and Gynecology Drugs Industry Drivers
- 4.3 Obstetrics and Gynecology Drugs Industry Opportunities and Challenges
- 4.4 Obstetrics and Gynecology Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Obstetrics and Gynecology Drugs Revenue (2021-2026)
- 5.2 Global Obstetrics and Gynecology Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Obstetrics and Gynecology Drugs Key Company Headquarters & Area Served
- 5.4 Global Obstetrics and Gynecology Drugs Company, Product Type & Application
- 5.5 Global Obstetrics and Gynecology Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Obstetrics and Gynecology Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Obstetrics and Gynecology Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Obstetrics and Gynecology Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Abbott
- 6.1.1 Abbott Company Information
- 6.1.2 Abbott Business Overview
- 6.1.3 Abbott Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Abbott Obstetrics and Gynecology Drugs Product Portfolio
- 6.1.5 Abbott Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Johnson & Johnson Obstetrics and Gynecology Drugs Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novartis Obstetrics and Gynecology Drugs Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Merck
- 6.4.1 Merck Company Information
- 6.4.2 Merck Business Overview
- 6.4.3 Merck Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Merck Obstetrics and Gynecology Drugs Product Portfolio
- 6.4.5 Merck Recent Developments
- 6.5 Roche
- 6.5.1 Roche Company Information
- 6.5.2 Roche Business Overview
- 6.5.3 Roche Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Roche Obstetrics and Gynecology Drugs Product Portfolio
- 6.5.5 Roche Recent Developments
- 6.6 Eli Lilly
- 6.6.1 Eli Lilly Company Information
- 6.6.2 Eli Lilly Business Overview
- 6.6.3 Eli Lilly Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Eli Lilly Obstetrics and Gynecology Drugs Product Portfolio
- 6.6.5 Eli Lilly Recent Developments
- 6.7 Pfizer
- 6.7.1 Pfizer Company Information
- 6.7.2 Pfizer Business Overview
- 6.7.3 Pfizer Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Pfizer Obstetrics and Gynecology Drugs Product Portfolio
- 6.7.5 Pfizer Recent Developments
- 6.8 Bayer
- 6.8.1 Bayer Company Information
- 6.8.2 Bayer Business Overview
- 6.8.3 Bayer Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Bayer Obstetrics and Gynecology Drugs Product Portfolio
- 6.8.5 Bayer Recent Developments
- 6.9 Amgen
- 6.9.1 Amgen Company Information
- 6.9.2 Amgen Business Overview
- 6.9.3 Amgen Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Amgen Obstetrics and Gynecology Drugs Product Portfolio
- 6.9.5 Amgen Recent Developments
- 6.10 Abbvie
- 6.10.1 Abbvie Company Information
- 6.10.2 Abbvie Business Overview
- 6.10.3 Abbvie Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Abbvie Obstetrics and Gynecology Drugs Product Portfolio
- 6.10.5 Abbvie Recent Developments
- 6.11 AstraZeneca
- 6.11.1 AstraZeneca Company Information
- 6.11.2 AstraZeneca Business Overview
- 6.11.3 AstraZeneca Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 AstraZeneca Obstetrics and Gynecology Drugs Product Portfolio
- 6.11.5 AstraZeneca Recent Developments
- 6.12 TherapeuticsMD
- 6.12.1 TherapeuticsMD Company Information
- 6.12.2 TherapeuticsMD Business Overview
- 6.12.3 TherapeuticsMD Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 TherapeuticsMD Obstetrics and Gynecology Drugs Product Portfolio
- 6.12.5 TherapeuticsMD Recent Developments
- 6.13 Lupin
- 6.13.1 Lupin Company Information
- 6.13.2 Lupin Business Overview
- 6.13.3 Lupin Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Lupin Obstetrics and Gynecology Drugs Product Portfolio
- 6.13.5 Lupin Recent Developments
- 6.14 GlaxoSmithKline
- 6.14.1 GlaxoSmithKline Company Information
- 6.14.2 GlaxoSmithKline Business Overview
- 6.14.3 GlaxoSmithKline Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 GlaxoSmithKline Obstetrics and Gynecology Drugs Product Portfolio
- 6.14.5 GlaxoSmithKline Recent Developments
- 6.15 Ferring
- 6.15.1 Ferring Company Information
- 6.15.2 Ferring Business Overview
- 6.15.3 Ferring Obstetrics and Gynecology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Ferring Obstetrics and Gynecology Drugs Product Portfolio
- 6.15.5 Ferring Recent Developments
7 North America
- 7.1 North America Obstetrics and Gynecology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 7.3 North America Obstetrics and Gynecology Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Obstetrics and Gynecology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 8.3 Europe Obstetrics and Gynecology Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Obstetrics and Gynecology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Obstetrics and Gynecology Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Obstetrics and Gynecology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 10.3 South America Obstetrics and Gynecology Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Obstetrics and Gynecology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Obstetrics and Gynecology Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst